Diclofenac Extended-Release Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 100 mg
Reference Brands: Voltaren(US & EU)
Category:
Arthritis
Diclofenac ER tablets inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which alleviates pain and inflammation. The extended-release formulation provides long-lasting relief, decreases dosing frequency, and improves compliance. Benefits include effective management of chronic pain, arthritis, and inflammatory conditions with sustained, predictable symptom control.
Diclofenac Extended-Release Tablets is available in Extended-Release Tablets
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Diclofenac Extended-Release Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Diclofenac Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Diclofenac ER (Extended-Release) tablets are approved in the EU and US for managing chronic pain and inflammation. In the EU, brands like Voltaren ER are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data and biosimilarity assessments, with generic versions available. Both regions require detailed dossiers for approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We help facilitate efficient market access for diclofenac ER tablets, ensuring adherence to European and American standards for safe, effective long-term anti-inflammatory therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing